These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 8117868

  • 1. [Multicenter clinical, double blind, and randomized study to assess the effectiveness and safety of binifibrate versus gemfibrozil in type IIa, IIb, and IV hyperlipidemia].
    Corominas Vilardell A, de Oya Otero M, Escobar Jiménez F, Anguera Vila A, Ariño Armengol B.
    An Med Interna; 1993 Nov; 10(11):537-41. PubMed ID: 8117868
    [Abstract] [Full Text] [Related]

  • 2. Gemfibrozil in hyperlipidaemia: an open, single blind trial.
    Varthakavi PK, Turakhia DP, Sharma SS, Salgaonkar DS, Nihalani KD, Joshi VR.
    J Assoc Physicians India; 1990 Feb; 38(2):136-40. PubMed ID: 2380132
    [Abstract] [Full Text] [Related]

  • 3. [Changes in the lipid profiles of hyperlipemic patients treated with binifibrate].
    Avellaneda A, Rueda A, Cascio C, Gutiérrez JA.
    An Med Interna; 1993 Jun; 10(6):275-9. PubMed ID: 8334204
    [Abstract] [Full Text] [Related]

  • 4. Gemfibrozil in dyslipidaemia.
    Kundu SC, Roxy S, Batabyal SK.
    J Assoc Physicians India; 1990 Feb; 38(2):156-9. PubMed ID: 2199426
    [Abstract] [Full Text] [Related]

  • 5. Fish oil supplementation versus gemfibrozil treatment in hyperlipidemic NIDDM. A randomized crossover study.
    Fasching P, Rohac M, Liener K, Schneider B, Nowotny P, Waldhäusl W.
    Horm Metab Res; 1996 May; 28(5):230-6. PubMed ID: 8738112
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia.
    Wolf HR.
    Drugs Exp Clin Res; 1994 May; 20(3):109-13. PubMed ID: 7956717
    [Abstract] [Full Text] [Related]

  • 7. [Multicenter comparative study on safety, tolerance, and effectiveness of lovastatin combined or not with cholestyramine, and gemfibrozil combined or not with cholestyramine in the treatment of primary hypercholesterolemia].
    Jover E, Aranda JL, Nogués X, del Palacio A, Rubiés-Prat J.
    Med Clin (Barc); 1996 May 25; 106(20):776-9. PubMed ID: 8801396
    [Abstract] [Full Text] [Related]

  • 8. [Gemfibrozil in the treatment of lipid metabolism disorders].
    Vartanova OA, Aleksandrovskaia TN, Shaldaeva VV.
    Klin Med (Mosk); 1994 May 25; 72(1):37-41. PubMed ID: 8196321
    [Abstract] [Full Text] [Related]

  • 9. [Modification of serum lipids, lipoproteins and apoproteins AI and B in patients with hyperlipidemia Type IIa and IIb using polyenylphosphatidylcholine].
    Noseda G, Suvà F, Fragiacomo C.
    Schweiz Med Wochenschr; 1985 Jul 27; 115(30):1064-70. PubMed ID: 4035328
    [Abstract] [Full Text] [Related]

  • 10. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
    Superko HR, Garrett BC, King SB, Momary KM, Chronos NA, Wood PD.
    Am J Cardiol; 2009 Feb 01; 103(3):387-92. PubMed ID: 19166694
    [Abstract] [Full Text] [Related]

  • 11. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct 01; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 12. The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome.
    Büyükçelik M, Anarat A, Bayazit AK, Noyan A, Ozel A, Anarat R, Aydingülü H, Dikmen N.
    Turk J Pediatr; 2002 Oct 01; 44(1):40-4. PubMed ID: 11858378
    [Abstract] [Full Text] [Related]

  • 13. [Effect of a new synthetic compound (3-nicotinoyl-oxypropyl p-chlorophenoxy isobutyrate: I.612) on plasma lipids in patients with type IIa, IIb and IV hyperdyslipidemia].
    Bucalossi A, Buzzelli G, D'Alessandro A.
    Clin Ter; 1979 Apr 30; 89(2):127-49. PubMed ID: 226307
    [No Abstract] [Full Text] [Related]

  • 14. Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizability.
    O'Neal DN, O'Brien RC, Timmins KL, Grieve GD, Lau KP, Nicholson GC, Kotowicz MA, Best JD.
    Diabet Med; 1998 Oct 30; 15(10):870-7. PubMed ID: 9796889
    [Abstract] [Full Text] [Related]

  • 15. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S.
    Metabolism; 2005 May 30; 54(5):677-81. PubMed ID: 15877299
    [Abstract] [Full Text] [Related]

  • 16. The effect of simvastatin on HDL cholesterol in hyperlipidemic patients. Evidence of a relationship with the changes in serum triglyceride level.
    Branchi A, Rovellini A, Fiorenza AM, Maraffi F, Gandini R, Sommariva D.
    Int J Clin Pharmacol Ther; 1996 Sep 30; 34(9):384-9. PubMed ID: 8880287
    [Abstract] [Full Text] [Related]

  • 17. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A.
    Superko HR, Berneis KK, Williams PT, Rizzo M, Wood PD.
    Am J Cardiol; 2005 Nov 01; 96(9):1266-72. PubMed ID: 16253595
    [Abstract] [Full Text] [Related]

  • 18. Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia.
    Vigna GB, Donega P, Passaro A, Zanca R, Cattin L, Fonda M, Pauciullo P, Marotta G, Fellin R, Gasparrini S, Piliego T.
    Nutr Metab Cardiovasc Dis; 1999 Oct 01; 9(5):234-43. PubMed ID: 10656170
    [Abstract] [Full Text] [Related]

  • 19. [Changes in blood viscosity and erythrocyte deformability in patients with dyslipidemia treated with binifibrate].
    Labiós Gómez M, Romero Simo M, Gabriel Botella F, Martín Valles H, Morera Llorca M, Freixas Ventura J.
    An Med Interna; 1990 Oct 01; 7(10):517-21. PubMed ID: 2104097
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
    Terra SG, Francone OL, Contant CF, Gao X, Lewin AJ, Nguyen TT.
    Am J Cardiol; 2008 Aug 15; 102(4):434-9. PubMed ID: 18678301
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.